博雅生物公告，公司拟通过上海联合产权交易所公开挂牌转让江西博雅欣和制药有限公司80%股权。首次挂牌金额为2.13亿元，交易对象、交易价格和交易时间尚未确定，交易成功与否存在不确定性。此次股权转让旨在优化公司资源配置，聚焦血液制品主业，提升资本回报水平。转让完成后，博雅欣和将不再纳入公司合并报表范围。公司将根据交易进展情况及时履行信息披露义务。此次交易不构成重大资产重组。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.